Zhejiang Medicine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	8,770	8,834	9,336	7,762	8,073	9,088
Other Revenue	46.23	46.23	38.76	32.11	43.23	41.3
Revenue	8,816	8,881	9,375	7,794	8,116	9,129
Revenue Growth (YoY)	-6.03%	-5.28%	20.29%	-3.96%	-11.10%	24.60%
Cost of Revenue	6,131	5,984	5,591	5,392	5,438	5,530
Gross Profit	2,685	2,896	3,785	2,402	2,678	3,599
Selling, General & Admin	1,403	1,409	1,678	1,481	1,312	1,546
Research & Development	496.23	579.88	749.35	860.07	809.28	806.86
Other Operating Expenses	44.07	51.37	53.85	52.3	69.86	75.17
Operating Expenses	1,940	2,037	2,494	2,394	2,188	2,439
Operating Income	745.4	859.52	1,291	7.98	489.74	1,160
Interest Expense	-24.82	-24.82	-26.37	-28.34	-33.11	-39.54
Interest & Investment Income	35.84	32.72	22.51	16.51	13.18	57.42
Currency Exchange Gain (Loss)	74.97	74.97	17.82	36.59	66.6	-64.31
Other Non Operating Income (Expenses)	-87.29	-5.2	3.9	21.09	-36.73	-2.69
EBT Excluding Unusual Items	744.1	937.2	1,308	53.83	499.67	1,111
Impairment of Goodwill	-	-	-18.68	-9.23	-8.12	-
Gain (Loss) on Sale of Investments	6.13	4.64	-29.6	-28.59	-56.51	51.73
Gain (Loss) on Sale of Assets	-4.24	-6.56	-5.21	323.57	-1.37	-7.95
Asset Writedown	16.34	-25.62	-69.41	-	-	-46.19
Other Unusual Items	42.07	42.07	26.77	23.69	57.71	44.76
Pretax Income	804.4	951.73	1,212	363.28	491.39	1,154
Income Tax Expense	171.05	191.49	192.03	86.48	128.77	268.97
Earnings From Continuing Operations	633.35	760.24	1,020	276.79	362.61	884.56
Minority Interest in Earnings	117.96	113.14	140.26	152.85	176.96	160.76
Net Income	751.31	873.38	1,161	429.64	539.57	1,045
Net Income to Common	751.31	873.38	1,161	429.64	539.57	1,045
Net Income Growth	-48.54%	-24.74%	170.11%	-20.37%	-48.38%	45.71%
Shares Outstanding (Basic)	956	955	959	955	964	959
Shares Outstanding (Diluted)	956	955	959	955	964	959
Shares Change (YoY)	0.91%	-0.42%	0.46%	-0.91%	0.47%	0.26%
EPS (Basic)	0.79	0.91	1.21	0.45	0.56	1.09
EPS (Diluted)	0.78	0.91	1.21	0.45	0.56	1.09
EPS Growth	-49.30%	-24.79%	168.89%	-19.64%	-48.62%	45.33%
Free Cash Flow	1,207	1,439	534.15	-162.56	-455.39	197.05
Free Cash Flow Per Share	1.26	1.51	0.56	-0.17	-0.47	0.20
Dividend Per Share	0.280	0.280	0.370	0.150	0.170	0.330
Dividend Growth	-24.32%	-24.32%	146.67%	-11.77%	-48.48%	43.48%
Gross Margin	30.46%	32.61%	40.37%	30.82%	33.00%	39.43%
Operating Margin	8.46%	9.68%	13.77%	0.10%	6.03%	12.71%
Profit Margin	8.52%	9.84%	12.38%	5.51%	6.65%	11.45%
Free Cash Flow Margin	13.69%	16.21%	5.70%	-2.09%	-5.61%	2.16%
EBITDA	1,452	1,569	2,013	732.17	1,171	1,747
EBITDA Margin	16.47%	17.67%	21.47%	9.39%	14.42%	19.14%
D&A For EBITDA	706.83	709.85	721.94	724.19	680.81	586.79
EBIT	745.4	859.52	1,291	7.98	489.74	1,160
EBIT Margin	8.46%	9.68%	13.77%	0.10%	6.03%	12.71%
Effective Tax Rate	21.26%	20.12%	15.84%	23.81%	26.21%	23.32%
Revenue as Reported	8,881	8,881	9,375	7,794	8,116	9,129
Advertising Expenses	-	9.45	18.46	21.25	19.59	21.3

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.